USA - NASDAQ:OMGA - US68217N1054 - Common Stock
Overall OMGA gets a fundamental rating of 2 out of 10. We evaluated OMGA against 534 industry peers in the Biotechnology industry. Both the profitability and financial health of OMGA have multiple concerns. While showing a medium growth rate, OMGA is valued expensive at the moment.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -47.86% | ||
| ROE | -633.21% | ||
| ROIC | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -4.95 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.61 | ||
| Quick Ratio | 1.61 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
0.1426
-0.02 (-10.82%)
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 0.98 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 0.68 | ||
| P/tB | 0.68 | ||
| EV/EBITDA | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -47.86% | ||
| ROE | -633.21% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 118.3% | ||
| Cap/Sales | 25.4% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.61 | ||
| Quick Ratio | 1.61 | ||
| Altman-Z | -4.95 |
ChartMill assigns a fundamental rating of 2 / 10 to OMGA.
ChartMill assigns a valuation rating of 1 / 10 to OMEGA THERAPEUTICS INC (OMGA). This can be considered as Overvalued.
OMEGA THERAPEUTICS INC (OMGA) has a profitability rating of 0 / 10.